(TSX-V:CYG),(AUST:CY5.AX),(OTC US:CYGGF),(OTCQB:CYGGF), Chibougamau Copper-Gold Project, Canada HIGHLIGHTS: Ongoing resource growth drilling at Cedar Bay has intersected a wide zone of mineralisation in what appears to be a new parallel zone: 28.9m at 2.5g/t AuEq (1.0g/t Au, 1.0% Cu & 12.0g/t Ag) (CDR-25-16) The result highlights the strong potential to keep growing the resource base within […]
Drilling hits wide zone of mineralisation in new area well outside resource Intersection of 28.9m at 2.5g/t AuEq just 200m from surface offers potential for additional resource growth; Follow-up drilling to start next week GlobeNewswire December 07, 2025 Chibougamau Copper-Gold Project, Canada HIGHLIGHTS: Ongoing resource growth drilling at Cedar Bay has intersected a wide zone
New York, New York–(Newsfile Corp. – December 7, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”), of the important January 9, 2026 lead plaintiff deadline in the securities
Washington, D.C., Dec. 07, 2025 (GLOBE NEWSWIRE) — A former CIA counter-terrorism officer's recent presentation is urging Americans to understand the full scale of China's military and technological rise, warning that the nation's rapid expansion in artificial intelligence and autonomous weaponry represents a shift with global consequences. According to former national security analyst Buck Sexton,
Former National Security Analyst Signals a Warning in Recent Presentation: “Most Americans are completely uninformed about China's ambition and power.” Buck Sexton Details China's Expanding AI Military Capabilities and Why He Thinks U.S. Officials Are Increasingly Alarmed GlobeNewswire December 07, 2025 Washington, D.C., Dec. 07, 2025 (GLOBE NEWSWIRE) — A former CIA counter-terrorism officer's recent
https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of agilon health, inc. (NYSE: AGL) resulting from allegations that agilon health may have issued materially misleading business information to the investing public. So What: If you purchased agilon health securities you may be
In addition to meeting the primary endpoint of non-inferiority foroverall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to78.5% for ibrutinib in the intent-to-treat (ITT) population Progression-free survival data were immature but trended in favor of pirtobrutinib with a 43% reduction of the risk of disease
(NASDAQ:REGN), All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of greater-than or equal to70% despite limited follow-up; evidence shows that these responses are expected to deepen over time Across all dose groups, 95% (19 of 20 patients) of all evaluable
(NASDAQ:LYEL), 93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L setting Manageable safety profile appropriate for
Lynozyfic(TM) (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment GlobeNewswire December 07, 2025 All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of greater-than or equal to70% despite limited